HomeNew Products

New Products

Cat.No. Product Name Information Added
E6603 USP5-IN-1 USP5-IN-1 (compound 64) is a selective competitive inhibitor targeting the zinc finger ubiquitin-binding domain (ZnF-UBD) of USP5, exhibiting a dissociation constant (KD) of 2.8 μM. This compound competitively inhibits ubiquitin binding to ZnF-UBD, suppresses USP5 catalytic activity, and consequently impedes ubiquitin chain hydrolysis. In vitro studies demonstrate its ability to inhibit USP5-mediated cleavage of Lys48-linked diubiquitin substrates, positioning it as both a potential chemical probe for USP5 and a candidate therapeutic agent for USP5-associated cancers. Nov 20 2025
E6614 FABPs ligand 6 (MF6) FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). Nov 20 2025
E6610 GPX4-IN-5 GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research. Nov 20 2025
E2949 Talarozole (R115866) Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy. Nov 20 2025
E1154 DS18561882 DS18561882 is a potent and isozyme-selective inhibitor of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), demonstrating an IC50 of 0.0063 μM. It also inhibits MTHFD1 with an IC50 of 0.57 μM. This compound displays favorable oral pharmacokinetic properties. Nov 20 2025
P1253 Allo-aca (ARV-1803) Allo-aca (ARV-1803) is a synthetic peptide that functions as a specific antagonist of the leptin receptor, effectively blocking leptin signaling in both in vitro and in vivo. It also demonstrates potential therapeutic applications in the treatment of ophthalmic diseases. Nov 20 2025
P1267 CIRC-014 CIRC-014 is an orally bioavailable cyclin A/B RxL macrocyclic inhibitor. CIRC-014 displays robust anti-tumor activity in chemo-resistant small cell lung cancer (SCLC) PDX models and induces SAC activation and apoptosis in vivo. Nov 20 2025
E6608 HSK31858 HSK31858 is a reversible inhibitor of DPP-1. It promotes the amelioration of neutrophilic inflammation, demonstrating efficacy and safety in reducing exacerbation frequency in adults with bronchiectasis. Nov 20 2025
E1963 ARV-393 ARV-393 is a highly potent, orally bioavailable BCL6 PROTAC degrader. ARV-393 promotes rapid BCL6 degradation through the cells ubiquitin-proteasome pathway. ARV-393 demonstrates DC50 and GI50 values <1 nM in numerous DLBCL and BL cell lines. Nov 19 2025
F5072 Cox1 Antibody [N11K4] Nov 12 2025
F4416 PGC1α/β Antibody [H5N22] Nov 12 2025
F4337 Claudin 7 Antibody [M7D16] Nov 12 2025
F4131 c-Fos Antibody [B8E19] Nov 12 2025
F4147 HER2/ErbB2 Antibody [G18G3] Nov 12 2025
F2178 CXCR4 Antibody [G11H20] CXCR4,CXCR-4 Nov 12 2025
E6559 GS-1427 GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease. Nov 12 2025
F3893 Phospho-PERK (Thr982) Antibody [A3P5] Nov 10 2025
E6539 SHOC2–RAS PPI-IN-1 SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor that disrupts the SHOC2-RAS protein-protein interaction. It exhibits an IC50 of 0.048 μM and a KD of 0.065 μM against NRASQ61R. The compound inhibits the SMP phosphatase complex, resulting in elevated CRAFS259 phosphorylation and subsequent blockade of the MAPK signaling pathway (evidenced by reduced pMEK and pERK levels). This inhibition induces tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 serves as a research tool for investigating NRASQ61R-mutant malignancies including melanoma and colorectal cancer. Nov 10 2025
F2955 MIF Antibody [M24J2] Nov 10 2025
E6589 2BAct 2BAct is a potent, orally bioavailable eIF2B activator exhibiting high selectivity (EC50 = 33 nM). It mitigates neurological impairments induced by persistent integrated stress response. This compound demonstrates blood-brain barrier penetration with enhanced solubility and pharmacokinetic properties compared to ISRIB trans-isomer. Nov 09 2025
E5972 ZINC00784494 ZINC00784494 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases viability, and attenuates AKT phosphorylation in SUM149 cells. This compound demonstrates promising research potential for inflammatory breast cancer (IBC) investigations. Nov 03 2025
E6536 Antalarmin hydrochloride Antalarmin hydrochloride is an orally active, non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist exhibiting a Ki value of 1 nM. This compound inhibits CRH-induced ACTH secretion and attenuates CRH-mediated and novelty-induced anxiety-like behaviors in preclinical models. Additionally, antalarmin hydrochloride demonstrates anti-inflammatory activity in arthritis models and reduces stress-induced gastric ulceration associated with irritable bowel syndrome. Nov 03 2025
E6534 Safusidenib Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective inhibitor of mutant IDH1. It demonstrates potent inhibition against mutant IDH1 while showing minimal activity against the wild-type enzyme. This compound exhibits antitumor effects in chondrosarcoma models. In vitro assays without preincubation, it inhibits IDH1R132H and IDH1R132C with IC50 values of 15 nM and 130 nM, respectively. Nov 03 2025
E6576 Valiltramiprosate ALZ-801 is an orally bioavailable small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor. As a valine-conjugated prodrug of tramiprosate, it demonstrates significantly enhanced pharmacokinetic properties and gastrointestinal tolerability compared to the parent compound. This agent represents an optimized therapeutic candidate for Alzheimer's disease treatment. Nov 03 2025
E5971 ZINC00640089 ZINC00640089 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases cell viability, and reduces AKT phosphorylation levels in SUM149 cells. This compound shows promising research potential for inflammatory breast cancer (IBC) studies. Oct 28 2025
E6541 PolQi2 PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, it demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies. Oct 28 2025
E6522 HRS-9821 PDE3/4-IN-2 (Compound 1) functions as a dual inhibitor targeting both PDE3 and PDE4 enzymes, exhibiting IC50 values of 0.13 nM for PDE3A and 50 nM for PDE4B1. This compound demonstrates potential for investigating PDE-associated pathologies including asthma, chronic obstructive pulmonary disease, sepsis, and nephritis. Oct 22 2025
E1076 Linperlisib Linperlisibis a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10). Oct 15 2025
E6577 1-Naphthohydroxamic acid 1-Naphthohydroxamic acid (Compound 2) demonstrates potent and selective inhibition of HDAC8 (IC50 = 14 μM), exhibiting significantly greater selectivity for HDAC8 compared to class I HDAC1 and class II HDAC6 (IC50 >100 μM). This compound does not elevate global histone H4 acetylation levels nor decrease total intracellular HDAC activity. Additionally, 1-naphthohydroxamic acid has been shown to promote tubulin acetylation. Oct 15 2025
F2333 Phospho-p70 S6K (Thr421/Ser424) Antibody [E5J12] p70 S6K phospho Thr421 Ser424,Phospho-p70 S6 Kinase (Thr421/Ser424) Oct 13 2025
F2518 Oct4 Antibody [K18A18] Oct3/4,Oct-3/4,Oct4,Oct-4,OCT-4 [POU5F1] Oct 13 2025
F0232 LATS1 Antibody [A5C10] LATS1,LATS1/WARTS Oct 13 2025
F3854 Periostin Antibody [C16F13] Oct 13 2025
F4076 PDGFR α Antibody [E14D18] Oct 13 2025
F4084 β-Catenin Antibody [E8L3] Oct 13 2025
F4087 Phospho-Akt1 (Ser473) Antibody [K10L8] Oct 13 2025
F4181 MMP-2 Antibody [C12L21] Oct 13 2025
F4220 Zap-70 Antibody [E5E23] Oct 13 2025
F4988 PSMA Antibody [A11C13] Oct 13 2025
F4221 STAT5 Antibody [B9G7] Oct 13 2025
F3245 IRF1 Antibody [H12G6] Oct 13 2025
E1242 Barbadin Barbadin is a selective β-arrestin/β2-adaptin interaction inhibitor with IC50 values of 19.1 μM (β-arrestin1) and 15.6 μM (β-arrestin2). It inhibits agonist-induced endocytosis of β2-adrenergic, V2-vasopressin, and angiotensin-II type-1 receptors. Additionally, this compound exhibits pro-apoptotic activity. Oct 12 2025
E6574 NLRP3 NLRP3/aim2-in-2 (compound 8) is a novel potent inhibitor exhibiting species-specific effects on NLRP3 and AIM2 inflammasome-dependent cell death, with an IC50 value of 0.2392 μM. Oct 10 2025
E6573 Neuropathiazol Neuropathiazol is a neuronal differentiation inducer that specifically promotes the neuronal differentiation of multipotent hippocampal neural progenitor cells. Oct 10 2025
E1955 TNG348 TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers . Oct 10 2025
E6596 LAP LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) serves as a free radical initiator. The radicals generated by LAP during bioprinting exhibit potential cytotoxicity and mutagenicity. Furthermore, LAP concentration influences the mechanical strength of 3D-printed scaffolds. The typical concentration range employed for curing is 0.05%-1%. Optimal mechanical properties and biocompatibility are achieved at 0.1% concentration, demonstrating the highest elastic modulus. Sep 29 2025
E6514 BI033 BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease. Sep 29 2025
E1829 Calderasib (MK-1084) Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research. Sep 25 2025
E7074 Sulfo-NHS-LC-Biotin sodium Sulfo-NHS-LC-Biotin sodium is a biotinylated amine-reactive ester compound that cannot cross the intact blood-retinal barrier. This reagent serves as a useful tool for evaluating vascular permeability in both cerebral and retinal vasculature. Sep 24 2025
E5854 XYD049 XYD049 (compound 7d) is a CRBN-based molecular glue targeting GSPT1 (DC50=19 nM), applicable for studying MYC-driven castration-resistant prostate cancer (CRPC). It demonstrates potent growth inhibition of 22Rv1 cells (IC50=7 nM) and exhibits in vivo antitumor activity. This compound downregulates CRPC-associated oncogenes (AR, AR-v7, PSA, c-Myc) in 22Rv1 cells. Structurally, it consists of: 1) a molecular glue linker (NH2-C5-NH-Boc), 2) a CRBN-recruiting E3 ligase ligand (Thalidomide 4-fluoride), and 3) a GSPT1-targeting moiety (GSPT1 ligand-1). The E3 ligase ligand-linker combination forms conjugate 158. Sep 24 2025
E1968 BBO-8520 BBO-8520 is a covalent small molecule inhibitor that selectively targets KRAS G12C with high oral bioavailability. It functions as both a KRAS G12C (OFF) inhibitor and a blocker of KRAS G12C (ON) signaling. This compound inhibits cellular proliferation by binding to GTP-bound KRAS G12C (ON), thereby preventing RAS-RAF1 interaction and promoting the transition to the inactive (OFF) state. Sep 24 2025
E6407 CD2665 CD2665 is an orally bioavailable selective antagonist of RAR-β and RAR-γ, exhibiting dissociation constants (Kd) of 306 nM for RAR-β and 110 nM for RAR-γ. Sep 24 2025
E6410 Peptide 4 Peptide 4 is a complex synthetic peptide molecule commonly used as a research chemical or therapeutic agent due to its potential to mimic biological peptides and modulate specific molecular targets. Sep 16 2025
S9959 Zotizalkib Zotizalkib(TPX-0131) is a compact macrocyclic potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations with an IC50 of 1.4 nM for wild-type ALK. It exhibits antitumor efficacy and can be used in non–small cell lung cancer research. Sep 14 2025
E4727 TYRA-300 TYRA-300 , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations. Sep 14 2025
E6547 crinecerfont crinecerfont (SSR-125543) is a selective antagonist of the corticotropin-releasing factor type 1 receptor (CRF1R). It lowers elevated adrenal androgens and steroid precursors in adolescents with congenital adrenal hyperplasia (CAH), including those with 21-hydroxylase deficiency. Sep 14 2025
E6580 Nusinersen Nusinersen is an 18-mer, 2′-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide used for treating spinal muscular atrophy (SMA). It binds specifically to the intronic splice silencer N1 (ISS-N1) site in intron 7 of SMN2 pre-mRNA, blocking the binding of splicing repressors hnRNP A1/A2. This promotes inclusion of exon 7 during splicing, restoring full-length SMN protein production in SMA patients. Sep 12 2025
E6581 Mipomersen Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH). Sep 12 2025
E1887 Sisunatovir hydrochloride Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection. Sep 07 2025
F0016 V5-Tag Antibody [K5J22] Paramyxovirus SV5 Pk,V5,V5 Epitope Tag,V5 Tag,V5-Probe,V5-Tag Sep 05 2025
F2801 MALT1/MLT Antibody [P2K2] MALT1,MALT1/MLT Sep 05 2025
F2459 Caspase-3 p12 Antibody [N15D21] caspase-3 p11,Caspase-3 p12 Sep 05 2025
F2516 mTOR Antibody [L10A18] Sep 05 2025
E6459 Phaclofen Phaclofen is a selective antagonist of GABAB receptor. Phaclofen is a peripheral and central baclofen antagonist that is used in determining the physiological significance of central and peripheral bicuculline-insensitive receptors with which GABA and (-)-baclofen interact. Sep 03 2025
S8027 GW1929 GW1929 is a potent and selective agonist of PPARγ with a pKi of 8.84 for human PPARγ and pEC50 of 8.56 and 8.27 in human and murine receptors, respectively. It exhibits potential clinical benefits in managing diabetic dyslipidemias and cardiovascular risk factors through its lipid-lowering effects and improved insulin sensitivity mediated by PPARγ activation. Sep 01 2025
E6478 ML115 ML115 is a molecular probe and a highly potent, selective agonist of STAT3 with an EC50 of 2.0 nM. It can be used in research on cancer, wound healing, cardiomyopathy, and inflammatory diseases. Aug 26 2025
E5885 JG-2016 JG-2016 is a potent and selective inhibitor of HAT1, with an IC50 of 14.8 μM and a binding KD of 22.5 μM for the HAT1:Rbap46 complex. It exhibits anti-proliferative activity with EC50 of 10.4 μM, 29.8 μM, and 1.9 μM in HCC1806, FICC1937, and A549 cells, respectively. JG-2016 significantly suppresses tumor growth in an A549 xenograft model. Aug 26 2025
E5817 Sevasemten Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy. Aug 26 2025
A2173 Anti-mouse L-Selectin (CD62L)-InVivo Anti-mouse L-Selectin (CD62L)-InVivo reacts with mouse CD62L also known as L-selectin and MEL-14. CD62L is a 76 kDa glycoprotein and a member of the selectin family. Aug 22 2025
A2174 Anti-mouse/human CD44-InVivo Anti-mouse/human CD44-InVivo reacts with human and mouse CD44 also known as Hermes, HCAM, and Pgp-1. CD44 is an 80-95 kDa glycoprotein that is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells. Aug 22 2025
E5989 PZL-A PZL-A is a activator of mitochondrial DNA (mtDNA) synthesis. PZL-A restores wild-type-like activity to mutant forms of polymerase γ (POLγ) with 160 nM for A467T and 20 nM for G848S. In cellular systems, PZL-A stimulates mtDNA synthesis, promoting oxidative phosphorylation complex biogenesis and improving cellular respiration. PZL-A is promising agent for relieving POLG disease and other severe conditions linked to depletion of mtDNA. Aug 20 2025
E6444 SSTC3 SSTC3 is a potent activator of casein kinase 1α (CK1α) with a Kd of 32 nM that inhibits WNTsignaling with an EC50 of 30 nM. It attenuates CRC cell growth through CK1α-dependent WNT pathway inhibition, offering an improved therapeutic index for targeting WNT-driven tumors. Aug 20 2025
E5992 VLS-1272 VLS-1272 is an orally bioavailable, potent, ATP non-competitive, microtubule-dependent, and highly selective inhibitor of KIF18A with an IC50 of 41 nM. It induces mitotic defects with strong anti-mitotic, anti-cancer, and anti-proliferative effects, leading to dose-dependent tumor growth inhibition and can be used for the study of cancers with high chromosomal instability. Aug 20 2025
E4693 AC-73 AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research. Aug 20 2025
E5970 PF-07853578 PF-07853578 (Example 11) is a degrader of Patatin-Like Phospholipase Domain-Containing Protein 3(PNPLA3) with an EC50 of 5.2 nM. It may be useful for the treatment and prevention of liver diseases, including fatty liver, nonalcoholic fatty liver disease (NALFD), nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma. Aug 20 2025
E6502 USP7-IN-1 USP7-IN-1 (Example 2) is a selective and reversible inhibitor of USP7 with an IC50 of 77 Μm and exhibits antiproliferative activity, inhibiting the growth of HCT116 colorectal cancer cells with a GI50 of 67 μM. Aug 20 2025
F3784 RHEB Antibody [L24C4] Aug 19 2025
F3880 NUMB Antibody [D4K1] Aug 19 2025
F3830 CX3CL1/Fractalkine Chemokine Domain Antibody [K3M15] Aug 19 2025
F0603 Phospho-YB1 (Ser102) Antibody [D17A16] Aug 19 2025
F3780 KLF4 Antibody [K21G5] Aug 19 2025
F3225 MCP1 Antibody [M3B19] CCL2 (MCP-1),CCL2/MCP1 Aug 19 2025
F3741 Monocyte + Macrophage Antibody [E17C4] Aug 19 2025
F3764 Phospho-Hsp27 (Ser82) Antibody [M1P19] Hsp27 (phospho S82),Phospho-HSP27 (Ser82),Phospho-HSP27 (Ser82) II Aug 19 2025
E5962 BRD-810 BRD-810 is a potent and highly selective inhibitor of MCL1. BRD-810 targets the BH3-binding pocket of MCL1 and blocks the capturing of pro-apoptotic proteins, thereby rapidly triggering caspase activation in MCL1-dependent cells. It demonstrates potent anti-tumor effects in both hematologic malignancies and solid tumor models. Aug 18 2025
E1566 Ensifentrine Ensifentrine (RPL-554) is a first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50 values of 0.4 nM and 1479 nM, respectively. Ensifentrine also inhibits lipopolysaccharide-induced tumor necrosis factor alpha release from human monocytes in a concentration-dependent manner. Ensifentrine demonstrates bronchoprotective and anti-inflammatory activities and can be used for chronic obstructive pulmonary disease (COPD) research. Aug 18 2025
E6471 JY-2 JY-2 is a selective and orally active inhibitor of the transcription factor forkhead box O1 (FoxO1). JY-2 suppresses FoxO1-driven transcriptional activity with an IC50 of 22 μM, and also exerts moderate inhibitory effects on FoxO3a and FoxO4. JY-2 also exhibits anti-diabetic properties. Aug 18 2025
E5984 ML339 ML339 is a potent and selective antagonist of CXCR6. ML339 antagonizes CXCL16-induced β-arrestin recruitment and cAMP signaling through the human CXCR6 receptor with IC50 values of 0.3 and 1.4 μM, respectively. ML339 shows no inhibitory activity against CXCR5, CXCR4, and CCR6. ML339 can be used as a potential agent for prostate cancer research. Aug 18 2025
E6477 Taurolithocholic acid Taurolithocholic acid is a taurine-conjugated tertiary bile acid. It induces apoptosis in hepatoma cell lines via caspase-3/7 activation and serves as a model to study the endocrine and metabolic roles of bile acids in enterohepatic circulation and liver physiology. Aug 14 2025
F3785 SIRT5 Antibody [G24H6] Aug 14 2025
F4266 PPARα Antibody [P17E1] Aug 14 2025
F3720 Pellino 1 Antibody [H22B1] Pellino 1,Pellino-1 Aug 14 2025
F3788 Flotillin 1 Antibody [J14F12] Flotillin 1,Flotillin-1 Aug 14 2025
F3760 PAN TEAD Antibody [A12P9] Pan-TEAD,TEAD4/TEF-1 Aug 14 2025
F3768 RAB10 Antibody [K22D15] Aug 14 2025
F3771 Mitofusin 1 Antibody [D5A17] MFN1,Mfn1/Mitofusin 1,Mitofusin 1,Mitofusin-1 Aug 14 2025
F1781 Mast Cell Tryptase Antibody [L14M18] Mast Cell Tryptase,TPSAB1,Tryptase,Tryptase Antibody, Mast Cell Aug 12 2025
E5997 Balinatunfib Balinatunfib (SAR441566) is an oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling. It binds to the central pocket of the soluble TNFα (sTNFα) trimer, alters its configuration, and prevents heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Balinatunfib exhibits anti-inflammatory activity and has the potential for use in autoimmune disease studies. Aug 12 2025
E6400 BSJ-5-63 BSJ-5-63 is a potent PROTAC degrader of CDK12, CDK7, CDK9. BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K, while also suppressing the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 demonstrates anticancer properties and has the potential for the research of prostate cancer. Aug 12 2025
E6500 Lignoceric acid Lignoceric acid is a 24-carbon saturated (24:0) fatty acid. In mammals, it is synthesized during brain development and is found in cerebrosides. The deficient peroxisomal oxidation of very-long-chain fatty acids, contributes to certain syndromes. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research. Aug 12 2025
E6484 E1231 E1231 (1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one) is a piperazine 1,4-diamide compound and an oral activator of SIRT1 with an EC50 of 0.83μM. It increases cholesterol efflux and decreases lipid accumulation in macrophages. E1231 regulates cholesterol and lipid metabolism in hyperlipidemic golden hamsters, with potential for atherosclerosis treatment. Aug 11 2025
E6486 VT3989 VT3989 (YAP/TAZ inhibitor-3) is a potent and selective oral inhibitor of TEAD auto-palmitoylation, blocking its interaction with yes-associated protein (YAP). It exhibits antitumor activity and shows potential for treating mesothelioma and solid tumors with NF2 mutations. Aug 11 2025
E6401 Vicadrostat Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research. Aug 07 2025
E5953 (S)-ACE-OH (S)-ACE-OH is a metabolite of the antipsychotic drug acepromazine. (S)-ACE-OH acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the nucleoporin NUP98 resulting in degradation of nuclear pore proteins and disruption of nucleocytoplasmic trafficking. It exhibits anti-cancer activity. Aug 07 2025
E6434 BPI-460372 BPI‑460372 is an orally available, covalent, irreversible inhibitor of TEAD 1/3/4 that binds to the cysteine residue in the TEAD palmitoylation pocket, preventing palmitoylation and inhibiting TEAD’s transcriptional activity. Aug 07 2025
E6458 ATF3 inducer 1 ATF3 inducer 1 (Compound 16c) is an achiral molecule that effectively induces ATF3 expression. It suppresses adipogenesis and enhances thermogenesis in an ATF3-dependent manner, improving glucose and lipid profiles in HFD-fed mice. It acts as a potential candidate for metabolic syndrome therapy. Aug 07 2025
E5857 GSK-872 hydrochloride GSK-872 hydrochloride is an inhibitor of RIPK3, which binds the RIP3 kinase domain with an IC50 of 1.8 nM and inhibits kinase activity with an IC50 of 1.3 nM. It exhibits the potential in alleviating early brain injury by inhibiting neuronal necroptosis and HMGB1-mediated inflammation. Aug 07 2025
E8307 Chloroquine dihydrochloride Chloroquine dihydrochloride acts as an inhibitor of autophagy and toll-like receptors (TLRs). Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Aug 07 2025
E5947 AZ3246 AZ3246 is a selective inhibitor of HPK1 with an IC50 value of <3 nM. AZ3246 induces IL-2 secretion in T cells with an EC50 of 90 nM and demonstrates antitumor activity in in vivo models. Aug 07 2025
E6419 RG6344 RG6344 (RO7276389) is a brain penetrant inhibitor of BRAF which is designed to overcome the MAPK paradoxical activity. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC). Aug 07 2025
E6041 Cephalexin hydrochloride Cephalexin (hydrochloride, Cefalexin hydrochloride) is a potent, orally active cephalosporin antibiotic with broad-spectrum activity. It acts by binding to penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis. Cephalexin hydrochloride demonstrates antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Aug 07 2025
E6482 STAT3-IN-12 STAT3-IN-12 is a potent inhibitor of STAT3signaling, by effectively blocking IL-6-induced activation of the JAK/STAT3 pathway. STAT3-IN-12 suppresses cancer cell proliferation and migration, while promoting apoptosis and inducing cell cycle arrest. Aug 07 2025
F2509 VEGFD Antibody [K3P16] Aug 04 2025
F3242 BACE1 Antibody [L19L22] BACE, BACE1 Aug 04 2025
F3323 AP2S1 Antibody [L13B7] Aug 04 2025
F3338 Smad1 Antibody [K19G18] Aug 04 2025
F3358 Phospho-Estrogen Receptor α (Ser118) Antibody [L4E1] Estrogen Receptor alpha (phospho S118),Phospho-Estrogen Receptor α (Ser118) Aug 04 2025
F3379 Fos B Antibody [G14F16] Fos B,FosB Aug 04 2025
F3447 PSF1 Antibody [E5F3] Aug 04 2025
F3600 SEP15 Antibody [A2N16] Aug 04 2025
F3628 HACE1 Antibody [A17B18] Aug 04 2025
E5921 ZSA-51 ZSA-51 is a potent oral agonist of STING. It exhibits potent antitumor efficacy in colon and pancreatic cancer, with superior oral PK, low toxicity, and immune microenvironment remodeling in tumors and lymph nodes. Aug 04 2025
E5766 DC-Y13-27 DC-Y13-27, a derivative of DC-Y13, is an inhibitor of YTHDF2 with a KD of 37.9 μM. It also upregulates FOXO3 and TIMP1 while downregulating MMP1, MMP3, MMP7, and MMP9. Additionally, it enhances the antitumor effects of radiotherapy and radio-immunotherapy and is implicated in intervertebral disc degeneration pathogenesis research. Aug 04 2025
E1928 Azelaprag Azelaprag (AMG 986) is a potent agonist of apelin receptor (APJ) with an EC50 of 0.32 nM. It exhibits potential and can be used in Heart failure (HF) research. Aug 04 2025
E5951 iZMYND8-34 iZMYND8-34 is a selective inhibitor of the histone reader ZMYND8 that blocks its histone recognition. Targeting ZMYND8 effectively suppresses antiandrogen-induced neuroendocrine transdifferentiation in prostate cancer, offering a promising approach to prevent neuroendocrine prostate cancer (NEPC) development. Jul 31 2025
E4758 ACBI3 ACBI3 is a selective and potent PROTAC degrader of pan-KRAS that promotes VHL engagement, ternary complex formation, and E3 ligase-dependent KRAS degradation with high proteome-wide selectivity. It demonstrates strong anti-tumor activity, resulting in durable pathway modulation and tumor regressions in KRAS driven cancers. Jul 31 2025
E5942 UNC9426 UNC9426 (compound 12) is a potent and orally bioavailable inhibitor of TYRO3 with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and effectively suppresses TYRO3-mediated signalling pathways in tumor cells and macrophages. Jul 31 2025
E6073 Solifenacin hydrochloride Solifenacin hydrochloride (YM905 hydrochloride) is an antagonist of muscarinic receptor used for the treatment of overactive bladder. It exhibits pKi values of approximately 7.6, 6.9, and 8.0 for the M1, M2, and M3 muscarinic receptors, respectively, in radioligand binding assays. Jul 31 2025
E4741 AZD4144 AZD4144 (Compound 25) is a potent and selective inhibitor of the NLRP3 inflammasome with an IC50 of 76 nM in the nigericin-triggered speck formation assay. It binds directly to the NACHT domain of NLRP3, stabilizing its inactive conformation to prevent inflammasome activation. AZD4144 also inhibits LPS/ATP-induced release of pro-inflammatory cytokines IL-1β and IL-18 in mice with an IC50 of 54 nM and exhibits potential for treating inflammatory diseases. Jul 31 2025
E6067 Frovatriptan succinate hydrate Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate, SB 209509 succinate) is a potent, selective and orally active agonist of 5-HT1B with pEC50 value of 8.2 and 5-HT1D receptor. It displays >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and a >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Jul 28 2025
E1609 NVP-CLR457 NVP-CLR457 is an orally active, potent, and balanced inhibitor of pan-class I PI3K. NVP-CLR457 exhibits IC50 values of 12 ± 1.5 nM, 8.3 ± 1.0 nM, 8.3 ± 2.0 nM, 230 ± 31 nM, for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ. It shows a clear dose-dependent PK/PD/efficacy relationship and demonstrates antitumor activity. Jul 28 2025
E6460 Phenamil methanesulfonate Phenamil methanesulfonate, is a potent and less reversible inhibitor of epithelial sodium channel (ENaC) with an IC50 of 400 nM. Phenamil methanesulfonate is also a competitive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca2+ transport with an IC50 of 140 nM in a Ca2+ uptake assay. Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease. Jul 28 2025
E5969 AZD2389 AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis. Jul 27 2025
E4605 Copanlisib dihydrochloride Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a selective and potent inhibitor of pan-class I PI3K. It significantly inhibits the catalytic activity of class I PI3K isoforms α, β, γ, and δ with IC50 of 0.5, 3.7, 6.4, and 0.7 nM, respectively. BAY 80-6946 exhibits potent antitumor activity in multiple cell-line–derived and patient-derived xenograft tumor models. Jul 27 2025
E5883 AM-9022 AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models. Jul 25 2025
E4658 Tilfrinib Tilfrinib (Compound 4f) is a potent and selective inhibitor of the tyrosine-protein kinase Brk/PTK6, with an IC50 of 3.15 nM. It demonstrates significant anti-proliferative activity against breast cancer cell lines MCF7, HS-578T, and BT-549. Jul 25 2025
E5863 α-NETA α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS). Jul 23 2025
E6408 CD1530 CD1530 is a potent and selective agonist of RARγ receptor with Ki values of 150 nM. It is a potent inhibitor of heterotopic ossification (HO) and may be effective against congenital HO, with potential use in research on psoriasis, acne, photoaging, and cancer. Jul 23 2025
E5960 PRDX1-IN-1 PRDX1-IN-1 is a celastrol-ligustrazine hybrid and a potent inhibitor of peroxiredoxin 1 (PRDX1) with an IC50 of 0.164 μM. It induces ROS accumulation, inhibits cancer cell growth and metastasis, and exhibits strong antitumor efficacy, making it a promising candidate for lung cancer therapy. Jul 23 2025
S9958 CB-6644 CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer. Jul 20 2025
E6463 Glycerophospholipids, cephalins Glycerophospholipids, cephalins are amphipathic molecules and essential components of neural membranes that are required for neural membrane structure and the proper function of integral membrane proteins, receptors, transporters, and ion channels. They also participate in apoptosis, regulate transporter and membrane-bound enzyme activities, and also serve as storage depots for lipid mediators and are useful in neurological disorder research, including Alzheimer's disease. Jul 17 2025
E5928 FAZ-3532 FAZ-3532 is a potent inhibitor of G3BP that binds to G3BP1 with a Kd of 0.54 μM, inhibiting co-condensation of G3BP1, Caprin1, and RNA, and blocking stress granule formation in cells. It specifically targets the protein–protein interaction within the NTF2L domain of G3BP1 without affecting its dimerization or RNA-binding, making it a useful tool to study the immunological role of stress granules during viral infection. Jul 17 2025
E4708 Etoposide phosphate Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. This compound also induces cell cycle arrest, apoptosis, and autophagy. Jul 15 2025
E8308 Alpelisib hydrochloride Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research. Jul 15 2025
E6435 CORM-401 CORM-401 is a water-soluble Carbon monoxide-releasing molecule that exhibits antioxidant and cytoprotective effects under oxidative stress conditions, including TNF-α/CHX and H₂O₂-induced damage. It induces nitric oxide production, activates the pentose phosphate pathway, and triggers distinct calcium signaling patterns, contributing to the regulation of endothelial function. Jul 15 2025
F3517 E-Cadherin Antibody [P11M9] E Cadherin,E-Cadherin,Uvomorulin/E-Cadherin Jul 14 2025
F3611 Clusterin Antibody [F10K16] Clusterin,Clusterin-α Jul 14 2025
F3695 LIF Antibody [G1M1] Jul 14 2025
F3757 Syk Antibody [M21H12] Jul 14 2025
F3640 Heme Oxygenase 1 Antibody [G7A14] Heme Oxygenase 1,Heme Oxygenase 1/HMOX1,HMOX1,HO-1 Jul 14 2025
F3879 HDAC1 Antibody [C7G4] Jul 14 2025
F0436 Insulin Antibody [K13G15] Jul 14 2025
F0646 Pdx1 Antibody [F18P8] Jul 14 2025
P1257 Nangibotide TFA Nangibotide TFA is a synthetic peptide that specifically inhibits the TREM‐1 (triggering receptor expressed on myeloid cells‐1) pathway by acting as a decoy receptor to block its activation. It reduces excessive inflammation, restores vascular function, and improves survival in animal models of septic shock. Jul 14 2025
E6425 VRK-IN-1 VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process. Jul 14 2025
E1521 SHR2554 SHR2554 is an inhibitor of EZH2. This compound exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels. Jul 14 2025
S9941 Emzadirib Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models. Jul 14 2025
E1767 HX531 HX531 is an orally active antagonist of RXR. This compound enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). It exhibits anti-obesity, anti-diabetic, and anti-melanoma properties. Jul 14 2025
F2703 HSP90α Antibody [F18G3] Jul 14 2025
F3548 PTEN Antibody [J22G2] Jul 14 2025
F3912 Phospho-JNK (Thr183) Antibody [D9B9] Jul 14 2025
F2822 HLA DR + DP + DQ Antibody [G22B16] HLA DR + DP + DQ,HLA-DR, DP, DQ Jul 10 2025
P1261 Cytochrome C Cytochrome c is a mitochondrial protein essential for electron transport and energy production. Upon apoptotic signals, it binds cardiolipin, gains peroxidase activity, and triggers cell death via caspase activation. Its function is tightly regulated by tissue-specific phosphorylation and ATP binding, which control respiration, ROS production, and apoptosis sensitivity. Jul 09 2025
E6000 BIEGi-1 BIEGi-1 is a potent and selective binary inhibitor of EGFR that effectively blocks EGFR-catalyzed nucleotide exchange and disrupts the EGFR–Rheb interaction. It robustly inhibits both EGFR kinase activity and mTORC1 signaling in EGFR-mutant cancer cells. This compound exhibits significant anti-proliferative effects with an IC50 of 17 nM for PC9 and 20 nM for HCC827. Jul 09 2025
S9966 SAFit2 SAFit2 is a highly potent and selective antagonist of FK506-binding protein 51 (FKBP51) with a Ki of 6 nM. It exhibits anxiolytic and antidepressant-like effects, regulates AKT2-AS160 signaling and metabolic function, and may be useful in research on stress-related disorders and type 2 diabetes. Jul 08 2025
F3688 Phospho-Hsp27 (Ser15) Antibody [D1B2] Hsp27 (phospho S15),Phospho-HSP27 (Ser15) Jul 08 2025
F3819 Cardiac Troponin T Antibody [G15H10] Jul 08 2025
F3506 DYKDDDDK Tag Antibody [C19M9] DDDDK tag (Binds to FLAG tag sequence),DYKDDDDK (FLAG(R) epitope tag),DYKDDDDK Epitope Tag,DYKDDDDK Tag,FLAG,Flag tag,FLAG(R),FLAG(R) M2,OctA-Probe Jul 08 2025
F0753 Phospho-YAP (Ser397) Antibody [B23M8] Jul 08 2025
E5874 INT-767 INT-767 is a dual agonist of farnesoid X receptor (FXR)/TGR5 with an EC50 of 0.033 μM and 0.67 μM, respectively. It significantly improves serum liver enzymes, hepatic inflammation, and biliary fibrosis, while inducing bile flow and biliary HCO₃⁻ output, making it a promising tool for chronic cholangiopathy research. Jul 08 2025
E6446 SD-2301 SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo. Jul 07 2025
F4578 Asparagine Synthetase Antibody [F20C4] Jul 06 2025
E6461 Cholesteryl hemisuccinate Cholesteryl hemisuccinate is a cholesterol derivative and a potent inhibior of DNA polymerase and DNA topoisomerase with an IC50 of 2.9 μM, 6.3 μM, 25 μM for Rat DNA polymerase β, Human DNA polymerase λ and Human DNA topoisomerase I respectively. It exhibits anticancer effect due to its ability to inhibit DNA replication, repair and cell division and can be used in cancer cell growth research. Jul 06 2025
E8311 Isoprenaline Isoprenaline is a synthetic, non-selective agonist of beta-adrenergic receptor and is used for the treatment of bradycardia, heart block, and congestive heart failure. Jul 04 2025
E5922 Enpatoran Enpatoran is a potent, selective inhibitor of Toll-like receptors 7 and 8 (TLR7/8), with IC50 of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. It also demonstrates potential for treating autoimmune diseases. Jul 04 2025
E5948 PB94 PB94 is a potent and selective inhibitor of HDAC11 with an IC50 of 108 nM and exhibits >40-fold selectivity over other HDAC isoforms. It ameliorates neuropathic pain in mouse models and can be radiolabeled with carbon-11 as [¹¹C]this compound for PET imaging, demonstrating significant brain uptake and potential for in vivo imaging applications. Jul 04 2025
F4580 COMT Antibody [E5A10] Jul 03 2025
E5880 Necrocide1 Necrocide1 is a potent inducer of cancer cell necrosis and displays antiproliferative activity with IC50 values of 0.48 nM and 2 nM for MCF-7 and PC3 cells, respectively. This compound also exerts potent antitumor effects in xenograft models. Jul 01 2025
E8310 Ribociclib succinate hydrate Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research. Jul 01 2025
E5990 Biotin-HPDP Biotin-HPDP is a thiol-specific biotinylating reagent that forms a reversible disulfide bond with free cysteine residues on proteins or peptides. It is widely used to selectively tag and detect sulfhydryl groups, especially in biochemical assays. In the Biotin Switch assay, this compound labels newly exposed cysteine thiols after reduction of S-nitrosylated or S-sulfhydrated proteins, enabling detection and purification via streptavidin-based methods. Jun 27 2025
E5893 MTT5 MTT5 is an agonist of TLR7 that activates dendritic cells and CD8⁺ T cells, enhancing immune responses in the tumor microenvironment. When linked to an ADC, it enhances antitumor efficacy through combined immune stimulation and cytotoxicity. Jun 27 2025
E4765 TYM-3-98 TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo. Jun 27 2025
E6077 Hydrocortisone cypionate Hydrocortisone cypionate is a synthetic corticosteroid and an ester form of hydrocortisone used primarily for treating inflammation and corticosteroid-responsive dermatoses. Jun 26 2025
E6078 Prednisolone Tebutate Prednisolone tebutate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester primarily used for its anti-inflammatory and immunosuppressive effects. It significantly suppresses inflammatory responses in models of monosodium urate (MSU) crystal-induced inflammation. Jun 26 2025
F2498 USP11 Antibody [D17E15] Jun 25 2025
F2598 TMPRSS2 Antibody [L10D17] Jun 25 2025
F3208 Nova1 Antibody [P4P2] Jun 25 2025
F3261 cIAP1 Antibody [B13P10] cIAP1,c-IAP1 Jun 25 2025
A2172 Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. All human nucleated cell express MHC class I antigens associated with β2-microglobulin. MHC class I plays a central role in cell-mediated immune responses and tumor surveillance. Jun 25 2025
E1027 Voclosporin Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research. Jun 24 2025
E5805 Ziresovir Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species. Jun 24 2025
P1255 Jagged-1 (188-204) (TFA) Jagged-1 (188-204) (TFA) is a peptide fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 also induces the maturation of monocyte-derived human dendritic cells. Jun 18 2025
E1576 LUNA18 LUNA18 (Paluratide) is an orally bioavailable 11-mer cyclic peptide KRAS inhibitor for the intracellular tough target RAS. It binds to KRASG12D with a kd of 0.043 nM and blocks KRASG12D–SOS1 interaction at IC50 of < 2.2 nM. It also exhibits antiproliferative activity in KRAS-mutant cancer cell lines with an IC50 of 1.4 nM in AsPC-1 pancreatic cancer cells. Jun 18 2025
E5988 SKLB-11A SKLB-11A is a selective, first-in-class allosteric activator of SIRT3 that binds with a Kd of 4.7 μM and enhances its deacetylase activity with EC50 of 21.95 μM. It improves cardiac function and alleviates myocardial damage in vivo. Jun 18 2025
E6426 Sulindac sulfide Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer's disease research. Jun 16 2025
E5999 CT1113 CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers. Jun 16 2025
E6402 GSK4418959 GSK4418959 (IDE275) is a non-covalent, reversible, selective, and orally bioavailable WRN helicase inhibitor. It exhibits ATP-competitive inhibition of both ATPase activity and DNA unwinding function. This compound serves as a research tool for investigating microsatellite instability-high (MSI-H) cancers. Jun 16 2025
E6403 RMC5127 RMC5127 is a first-in-class, orally bioavailable mutant-selective tri-complex inhibitor of the GTP-bound (ON) form of RASG12V. It non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding. It inhibits the RAS pathway in KRASG12V-mutant cancer cells, reducing proliferation, inducing apoptosis, and showing strong potential for use in RASG12V-mutated cancer research. Jun 16 2025
E6404 BMS-986449 BMS-986449 is a CELMoD molecular glue compound that functions as an IKZF2/IKZF4 degrader. This agent specifically mediates the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. Through CRBN (Cereblon)-mediated ubiquitination, this compound induces proteasomal degradation of these targets, leading to Treg cell reprogramming and subsequent enhancement of antitumor immune responses. The agent demonstrates potential for investigation in advanced solid malignancies. Jun 16 2025
E6405 AZD0022 AZD0022 is a potent, orally bioavailable, selective, reversible inhibitor of KRASG12D that drives robust pathway inhibition and anti-tumour activity in KRASG12D models. Jun 16 2025